Comparative efficacy of eight therapeutic methods in the treatment of left main coronary artery disease: a Bayesian

Biao Hou1, Manlin Chen2, Qin Li1

  • 1Inner Mongolia Medical University, Hohhot, China.

BMJ Open
|January 23, 2023
PubMed

Insights

This network meta-analysis compares surgical treatments for left main coronary artery (LMCA) disease. It aims to rank the long-term efficacy and safety of various surgical methods for LMCA lesions.

Area of Science:

  • Cardiovascular Surgery
  • Interventional Cardiology
  • Evidence-Based Medicine

Background:

  • Direct comparative studies on minimally invasive versus traditional thoracotomy for coronary artery bypass grafting are numerous.
  • However, a comprehensive ranking and summary of all surgical methods for left main coronary artery (LMCA) lesions are lacking.
  • Existing views on LMCA disease treatment remain controversial.

Purpose of the Study:

  • To conduct a planned network meta-analysis (NMA) comparing the long-term efficacy and safety of multiple therapeutic methods for LMCA disease.
  • To provide a reference for selecting optimal clinical strategies for LMCA lesions.
  • To address the current lack of ranked evidence for surgical interventions in LMCA disease.

Main Methods:

  • A systematic literature search of PubMed, Embase, Web of Science, and The Cochrane Library from inception to June 2022.
  • Inclusion of randomized controlled trials (RCTs) evaluating different surgical methods for LMCA disease.
  • Bayesian network meta-analysis using STATA V.16.0, assessing methodological quality via the Cochrane risk of bias tool.

Main Results:

  • Primary outcomes include major adverse cardiovascular events (mortality, myocardial infarction, stroke, revascularization).
  • Secondary outcomes encompass operation-related time, blood transfusion, complications (e.g., atrial fibrillation, wound infection), functional scores, return to work, and costs.
  • The NMA will provide a ranked comparison of surgical interventions for LMCA disease.

Conclusions:

  • This study will synthesize evidence to rank surgical interventions for LMCA disease.
  • The findings will inform clinical decision-making for treating LMCA lesions.
  • A comprehensive comparison of efficacy and safety will be presented.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
20
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
612
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
22